P2RY12 and coronary artery disorder: Finally, an individual patient data meta-analysis of24,325 patients from seven randomized trials compared P2Y12-i monotherapyand aspirin in patients with established coronary artery disease: compared toaspirin, P2Y12-i monotherapy reduced the risk of the composite ofcardiovascular death, MI or stroke (5.5% vs. 6.3%; HR 0.88; 95% CI 0.79 to0.97; p = 0.014), mainly driven by a reduction in MI (2.3% vs. 3.0%;HR 0.77; 95% CI 0.66 to 0.90; p < 0.001).